2026-2034年全球藥物和基因遞送系統市場規模、佔有率、趨勢和成長分析報告

預計到 2034 年，醫藥和基因輸送系統市場規模將從 2025 年的 46 億美元成長至 113.4 億美元，2026 年至 2034 年的複合年成長率為 10.56%。

由於先進治療方法的開發和對標靶藥物遞送技術需求的不斷成長，全球藥物和基因遞送系統市場正經歷顯著成長。基因遞送系統在現代生物技術和基因治療中發揮著至關重要的作用，能夠將遺傳物質高效遞送到細胞內以達到治療目的。慢性病和遺傳性疾病的日益普遍推動了對能夠改善治療效果的創新遞送技術的需求。

基因治療和生物技術研究的快速發展是推動該市場成長的主要因素之一。製藥和生物技術公司正大力投資開發病毒和非病毒遞送系統，以提高治療的精準性和安全性。此外，對個人化醫療和標靶治療日益成長的關注也加速了先進藥物和基因傳遞平台在臨床應用中的普及。

隨著基因療法獲得更廣泛的監管核准和臨床應用，市場預計將顯著擴張。基於奈米技術的遞送系統和生物材料的持續技術創新將進一步提高治療效率。新興市場對生物技術研究投入的增加以及醫療基礎設施的擴建，預計也將在未來幾年創造強勁的成長機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球藥物與基因遞送系統市場：依遞送系統分類

• 市場分析、洞察與預測
• 藥物傳輸系統（子宮內植入式、前驅藥物植入式、聚合物藥物傳輸、標靶藥物傳遞）

第5章 全球藥物與基因遞送系統市場：依基因遞送系統分類

• 市場分析、洞察與預測
• 病毒基因導入
• 非病毒基因轉移
• 混合系統

第6章 全球藥物與基因傳遞系統市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物
• 吸入
• 經皮
• 眼科
• 鼻腔
• 局部行政部門

第7章 全球藥物與基因傳遞系統市場：依應用分類

• 市場分析、洞察與預測
• 感染疾病
• 腫瘤學
• 眼科
• 泌尿系統
• 糖尿病
• 中樞神經系統
• 其他

第8章 全球藥物與基因傳遞系統市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Novartis AG
  • Amgen Inc
  • Oxford BioMedica Plc
  • SIBIONO
  • Shanghai Sunway Biotech Co. Ltd
  • F. Hoffmann-La Roche Ld
  • Pfizer Inc
  • Bayer AG
  • Johnson & Johnson Services Inc
  • Becton, Dickinson And Company
  • AstraZeneca Plc
  • Baxter International Inc
  • Boston Scientific Corporation
  • GenVivo Inc

The Drugs and Gene Delivery Systems Market size is expected to reach USD 11.34 Billion in 2034 from USD 4.60 Billion (2025) growing at a CAGR of 10.56% during 2026-2034.

The global drugs and gene delivery systems market is witnessing significant growth due to the increasing development of advanced therapeutics and the rising demand for targeted drug delivery technologies. Gene delivery systems play a crucial role in modern biotechnology and gene therapy by enabling the efficient transfer of genetic material into cells for therapeutic purposes. The growing prevalence of chronic diseases and genetic disorders is driving the demand for innovative delivery technologies that improve treatment effectiveness.

One of the key drivers of this market is the rapid advancement in gene therapy and biotechnology research. Pharmaceutical and biotechnology companies are investing heavily in the development of viral and non-viral delivery systems to enhance treatment precision and safety. In addition, the increasing focus on personalized medicine and targeted therapies is accelerating the adoption of advanced drug and gene delivery platforms in clinical applications.

Looking ahead, the market is expected to expand significantly as gene-based treatments gain wider regulatory approval and clinical adoption. Continuous technological innovation in nanotechnology-based delivery systems and biomaterials will further enhance treatment efficiency. Increasing investments in biotechnology research and expanding healthcare infrastructure in emerging markets are also expected to create strong growth opportunities in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Delivery System

• Drug Delivery Systems (lntrauterine Implants, Prodrug Implants, Polymeric Drug Delivery, Targeted Drug Delivery)

By Gene Delivery Systems

• Viral Gene Delivery
• Non-viral Gene Delivery
• Combined Hybrid System

By Route of Administration

• Oral
• Injectable
• Inhalation
• Transdermal
• Ocular
• Nasal
• Topical

By Application

• Infectious Diseases
• Oncology
• Ophthalmology
• Urology
• Diabetes
• CNS
• Others

COMPANIES PROFILED

• Novartis AG, Amgen inc, Oxford BioMedica plc, SIBIONO, Shanghai Sunway Biotech Co Ltd, F HoffmannLa Roche Ld, Pfizer Inc, Bayer AG, Johnson Johnson Services Inc, Becton, Dickinson and Company, AstraZeneca plc, Baxter International Inc, Boston Scientific Corporation, GenVivo Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET: BY DELIVERY SYSTEM 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Delivery System
• 4.2. Drug Delivery Systems (lntrauterine Implants, Prodrug Implants, Polymeric Drug Delivery, Targeted Drug Delivery) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET: BY GENE DELIVERY SYSTEMS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Gene Delivery Systems
• 5.2. Viral Gene Delivery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-viral Gene Delivery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Combined Hybrid System Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Inhalation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Transdermal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Ocular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Nasal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Ophthalmology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Urology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.7. CNS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Delivery System
  • 8.2.2 By Gene Delivery Systems
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Application
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Delivery System
  • 8.3.2 By Gene Delivery Systems
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Application
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Delivery System
  • 8.4.2 By Gene Delivery Systems
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Application
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Delivery System
  • 8.5.2 By Gene Delivery Systems
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Application
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Delivery System
  • 8.6.2 By Gene Delivery Systems
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Application
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL DRUGS AND GENE DELIVERY SYSTEMS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Novartis AG
  • 10.2.2 Amgen Inc
  • 10.2.3 Oxford BioMedica Plc
  • 10.2.4 SIBIONO
  • 10.2.5 Shanghai Sunway Biotech Co. Ltd
  • 10.2.6 F. Hoffmann-La Roche Ld
  • 10.2.7 Pfizer Inc
  • 10.2.8 Bayer AG
  • 10.2.9 Johnson & Johnson Services Inc
  • 10.2.10 Becton, Dickinson And Company
  • 10.2.11 AstraZeneca Plc
  • 10.2.12 Baxter International Inc
  • 10.2.13 Boston Scientific Corporation
  • 10.2.14 GenVivo Inc